Research aims to improve interstitial lung disease prognosis with new imaging agent
Researchers at the University of Exeter and clinical radiopharmaceutical company Serac Healthcare Ltd are researching a new molecular imaging marker...
interstitial
Phase II PREDICT-ILD Imaging Study Commences in Interstitial Lung Disease
LONDON, Sept. 10, 2024 /PRNewswire/ -- Serac Healthcare Limited ("Serac Healthcare" or "the Company"), a clinical radiopharmaceutical company developing innovative...
